Tafasitamab plus lenalidomide versus Pola-BR, R2, and CAR T: Comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed/refractory diffuse large B-cell lymphoma

According to data from the RE-MIND2 trial presented during the 2021 ASH Annual Meeting, tafasitamab plus lenalidomide provided an overall survival benefit compared with standard treatment options—including polatuzumab vedotin/bendamustine/rituximab (HR 0.44, 95% CI: 0.20-0.96; p=0.038) and rituximab/lenalidomide (HR 0.44, 95% CI: 0.22-0.84; p=0.014)—among patients with relapsed/refractory DLBCL ineligible for autologous stem cell transplant.